The French group Carmat, designer of an artificial heart, announced Thursday that it had raised 31.1 million euros, including approximately 27 million euros subscribed by specialized investors, via the issue of new shares.
The company plans to use the proceeds of this fundraising to support the development of its activities and in particular the ramp-up of its production, the recovery and growth of sales of its Aeson heart and the launch of a clinical study. in France, she said in a press release.
This operation, for a total amount of 31.1 million euros, was carried out by issuing 2.96 million new ordinary shares, representing 15% of the group's capital.
The issue price of the new shares was set at 10.5 euros per share, representing a discount of 19.8% compared to the closing price of the Carmat share on December 7.
The company recently announced the resumption of its establishments in France and Europe.
Carmat had obtained CE marking in Europe in December 2020 for its heart, as a “
bridge to transplantation
”, that is to say for patients awaiting heart transplantation.
But the company had suspended its implantations in December 2021, after incidents had affected some of its prostheses.
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/KMEYMJKESBAZBE4MRBAM4TGHIQ.jpg)
